Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer

被引:2
|
作者
Azzouzi, Abdel-Rahmene
Larre, Stephane
Cormier, Luc
Roupret, Morgan
Valeri, Antoine
Mangin, Philippe
Berthon, Philippe
Villette, Jean-Marie
Fiet, Jean
Cussenot, Olivier
机构
[1] CHU Angers, Dept Urol, F-49933 Angers, France
[2] CeRePP, UPRES, UFR, Biomed St Peres, Paris, France
[3] CHU Nancy Brabois, Dept Urol, Vandoeuvre Les Nancy, France
[4] CHU Cavale Blanche, Brest, France
[5] UroGene, Evry, France
[6] Hop St Louis, Dept Hormonol, Paris, France
[7] Inst Univ France, Paris, France
关键词
PSA; mass screening; prostate cancer; population surveillance;
D O I
10.1111/j.1464-410X.2006.06701.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: To assess the reliability of a new measurement of prostate-specific antigen (PSA) using a blotting-paper assay (nanotest) compared to the standard PSA immunoassay. SUBJECTS AND METHODS: The PSA level was measured in 205 men volunteers (median age 70 years, range 41-75) using a nanotest and a standard PSA immunoassay, collected at the same time; 30 mu L of capillary blood placed on to a blotting paper were collected for the nanotest and sent by mail to the same laboratory for the two assays. The results were compared statistically using the Spearman test, the intraclass correlation coefficient and the Bland-Altman test. RESULTS: The nanotest threshold for an abnormal PSA level was 78 pg/mL, which corresponded to a standard PSA value of 3 ng/mL, with a sensitivity of 100%. There was a significant correlation (r = 0.98, Spearman test; P < 0.001) between the nanotest and the standard PSA assay. The intraclass correlation coefficient was 0.87. The Bland-Altman test showed a good agreement between the nanotest and the standard PSA assay, but there was an increasing proportional difference with increasing PSA value. CONCLUSION: There was a very high correlation between the nanotest and the standard PSA assay, especially for standard PSA levels of < 5 ng/mL. Economic and clinical studies are indicated to confirm the utility of the nanotest in organized mass screening of prostate cancer.
引用
收藏
页码:762 / 764
页数:3
相关论文
共 50 条
  • [21] Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA
    Severi, Gianluca
    Hayes, Vanessa M.
    Neufing, Petra
    Padilla, Emma J. D.
    Tilley, Wayne D.
    Eggleton, Sarah A.
    Morris, Howard A.
    English, Dallas R.
    Southey, Melissa C.
    Hopper, John L.
    Sutherland, Robert L.
    Boyle, Peter
    Giles, Graham G.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (06) : 1142 - 1147
  • [22] BIOCHEMISTRY OF PROSTATE-SPECIFIC ANTIGEN, PSA
    MALM, J
    LILJA, H
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1995, 55 : 15 - 22
  • [23] Prostate-Specific Antigen (PSA) Bounces Following Stereotactic Body Radiotherapy for Prostate Cancer: Importance of PSA Test Frequency
    Kang, Ki Mun
    Choi, Hun Sik
    Jang, Hong-Seok
    Song, Jin-ho
    UROLOGY JOURNAL, 2024, 21 (06) : 384 - 389
  • [24] Verification bias in the assessment of prostate specific antigen (PSA) as a screening test for prostate cancer
    Gupta, A
    Roehrborn, CG
    JOURNAL OF UROLOGY, 2004, 171 (04): : 474 - 474
  • [25] Prostate-specific antigen (PSA) and radiotherapy in locally confined prostate cancer
    Schaefer, U
    Micke, O
    Willich, N
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2645 - 2648
  • [26] Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer
    Nordstrom, Tobias
    Akre, Olof
    Aly, Markus
    Gronberg, Henrik
    Eklund, Martin
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (01) : 57 - 63
  • [27] Prostate-specific antigen (PSA): A tumor marker in the diagnosis of prostate cancer
    Ohlendorf D.
    Wanke E.M.
    Braun M.
    Oremek G.M.
    Groneberg D.A.
    Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, 2017, 67 (4) : 221 - 223
  • [28] Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer
    Tobias Nordström
    Olof Akre
    Markus Aly
    Henrik Grönberg
    Martin Eklund
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 57 - 63
  • [29] Anti-PSA MAbs and prostate-specific antigen (PSA)
    Chou, SF
    HYBRIDOMA AND HYBRIDOMICS, 2004, 23 (02): : 150 - 150
  • [30] ASSOCIATION OF SEXUAL IDENTITY AND ACTIVITY WITH PROSTATE-SPECIFIC ANTIGEN (PSA) IN A PROSTATE CANCER SCREENING POPULATION
    Herkommer, K.
    Hollerer, M.
    Meissner, V. H.
    Schiele, S.
    Kron, M.
    Albers, P.
    Arsov, C.
    Imkamp, F.
    Hohenfellner, M.
    Hadaschik, B.
    Gschwend, J. E.
    JOURNAL OF SEXUAL MEDICINE, 2019, 16 (05): : S37 - S37